Abstract

ABSTRACT.As the fight against the coronavirus disease 2019 (COVID-19) pandemic continues, the necessity for wide-scale, global vaccine rollout to reduce the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and slow its mutation rate remains unassailable. The COVID-19 Vaccines Global Access (COVAX) initiative’s campaign involves a proportional framework to finance and distribute SARS-CoV-2 vaccines in low- and middle-income countries. However, the COVAX framework has critical limitations, including limited funding and the failure to account for the special epidemic risks and needs of its participating nations, as recommended by the World Health Organization’s Strategic Advisory Group of Experts on Immunization framework. These drawbacks disproportionately impact Africa, where many nations rely on COVAX as their main source of vaccines. The current plan to vaccinate only up to 20% of participating nations’ populations is short-sighted from both epidemiologic and moral perspectives. COVAX must commit to vaccinating all of Africa and its initiative must be modified to account for the health and economic infrastructures in these countries. Lessons learned from successful vaccination campaigns, including the West African Ebola outbreak, have shown that vaccinating all of Africa is possible and feasible, and that infrastructure and human resources can support mass vaccination. To halt this global pandemic, global responsibility must be accepted to finance and equitably distribute SARS-CoV-2 vaccines to African nations. We urge COVAX to act swiftly to prevent Africa from becoming the new face of a persisting pandemic.

Highlights

  • To end the coronavirus disease 2019 (COVID-19) pandemic, we must reach worldwide community immunity

  • With more than 190 participating countries, COVAX plans to finance and distribute two billion vaccine doses, with the goal of vaccinating up to 20% of participating countries’ populations.[3]. This is a welcome first step, but it is not an equitable solution, especially for African nations that must rely on COVAX as their main source of vaccines

  • It is true that more doses will be allocated eventually based on the needs of the nations,[7] COVAX has been stymied in providing the number of vaccines needed to reach 20% because of insufficient funding, vaccine hoarding in high-income countries, and limited capacity to produce vaccines globally as a result of the assertion of intellectual property rights

Read more

Summary

Introduction

To end the coronavirus disease 2019 (COVID-19) pandemic, we must reach worldwide community immunity. COVAX should immediately commit to providing 100% coverage to low-income African nations.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.